Harbin Yuyantang Traditional Chinese Medicine Outpatient Group Co. Ltd. has filed for an initial public offering in Hong Kong, capitalizing on robust financial performance and favorable regulatory tailwinds for the traditional Chinese medicine (TCM) sector. The filing reveals that the company’s revenue grew by 43.1% year-over-year to 183 million yuan, while net profit surged by 41.3% to 24.22 million yuan during the first five months of 2026. This growth trajectory positions the Harbin-based provider as a key beneficiary of China’s expanding "silver economy" and state-backed initiatives to revitalize TCM.

The IPO prospectus highlights that Yuyantang is the fifth-largest private provider of TCM medical services in China, holding a 2.3% national market share and leading the North China region with a 7% share. Founded in 2015 by Guo Yang, the company operates 59 offline physical institutions as of May 2026, primarily focusing on outpatient centers and clinics that treat chronic conditions such as hypertension, diabetes, and insomnia. Unlike competitors relying on franchise models, Yuyantang maintains direct ownership and operation of all its facilities to ensure uniform clinical protocols and brand standards.

Financial Performance and Revenue Drivers

Prescription preparations remain the core revenue driver, accounting for 92.4% of total income in the January–May 2026 period. This segment generated 169 million yuan ($25 million), representing a 40% year-over-year increase. The business model leverages both personalized TCM preparations, tailored to individual patient constitutions, and standardized in-hospital formulations approved for repeated use. Despite a slight contraction in gross margin from 62.6% in 2025 to 61.6% in the first five months of 2026, top-line growth successfully offset the margin decline, propelling overall profitability higher.

Market Context and Industry Outlook

The domestic market for TCM prescription preparations reached 63.4 billion yuan in 2025 and is projected to expand to 105.8 billion yuan by 2030, according to data cited in the listing document. This expansion is supported by central government policies, including the "15th Five-Year Plan for Traditional Chinese Medicine Development" and the "Health China 2030" Plan Outline. However, the industry remains highly fragmented, with the top five private chains controlling only 21% of the market. This consolidation opportunity suggests potential for M&A activity among major players like Yuyantang.

What the Numbers Show

A critical observation from the filing is the divergence between volume-driven revenue growth and margin compression. While average revenue per patient increased modestly by 1.1% to 443 yuan, the gross margin declined by one percentage point. This suggests that while Yuyantang is successfully acquiring more patients and increasing transaction values, it may be facing rising input costs or operational expenses associated with rapid network expansion. Additionally, the company’s profitability stands in stark contrast to peer PuraPharm (1498.HK), which reported a loss of HK$35.22 million in 2025 despite HK$336 million in revenue. Yuyantang’s full-year 2025 revenue was 400 million yuan with a 163% profit surge to 67.3 million yuan, indicating superior operational efficiency within the private TCM sector.